anemia News
-
Nepal looks to introduce fortified flour at small mills to reduce anemia
Nepal will enlist the help of small millers to boost the production of fortified cereal flour, which can help reduce anemia and other illnesses linked to vitamin and mineral deficiencies, particularly in poor, rural areas. To support the government’s goal, the Japan Fund for Poverty Reduction (JFPR) — financed by the Government of Japan and administered by the Asian Development Bank — is ...
-
Daxor Corporation Presents New Data Validating the Benefit of the BVA-100 Blood Test for Optimal Heart Failure Management at Key Scientific Society Meeting
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 blood test in identifying heart failure patient-specific phenotypes and detecting true anemia. These data from two separate studies were presented at the American Heart Association (AHA) Scientific Sessions virtual meeting from ...
-
Nova Blood Gas Analyzers Add Important New Test: Mean Corpuscular Hemoglobin Concentration (MCHC)
Waltham, MA - Nova Biomedical announces the addition of another important critical care parameter to its Stat Profile Prime Plus blood gas analyzer—the ability to rapidly calculate and report mean corpuscular hemoglobin concentration (MCHC). MCHC is a measure of the hemoglobin concentration in a given volume of packed red blood cells. MCHC, along with measured hemoglobin and ...
-
Smartphone-based saliva test that can detect COVID-19 earns UF professor honors in national contest
A University of Florida professor and his industry collaborators have won second place in a technology competition sponsored by the National Institutes of Health for a smartphone-based, rapid saliva test they developed that can be used to diagnose COVID-19, along with two other diseases of major global importance, malaria and anemia. A team consisting of Rhoel Dinglasan, Ph.D., a professor of ...
By Clip Health
-
Fera MAX NAMED #1 Recommended I Ron Supplement in Canada By Pharmacists and Physicians for Seventh Consecutive Year
MISSISSAUGA, ONTARIO (May 2,2022) BioSyent Inc. ("BioSyent", TSX Venture: RX) is pleased to announce that for the seventh consecutive year, FeraMAX® is the #1 recommended iron supplement brand in Canada based on a national survey of Canadian pharmacists and physicians.1 This annual survey was conducted by EnsemblelQ, Research, Insights and Innovation team and the following publications and ...
-
New resource to help older adults prevent carbon monoxide poisoning
Do you know how to tell the difference between carbon monoxide (CO) poisoning and the flu? The answer to this and other questions about preventing carbon monoxide poisoning can be found in a new fact sheet developed by EPA. Symptoms could be the result of CO poisoning when you feel better when you are away from home or the symptoms occur or get worse shortly after turning on a fuel-burning ...
-
BIO CEO Defends Dr. Fauci, Says Criticisms `Undermine Our Response to this Pandemic`
In response to attacks on Dr. Anthony Fauci’s credibility and character, BIO President and CEO Dr. Michelle McMurry-Heath issued the following statement: “As this global pandemic continues to wreak havoc, we must stand behind the scientists and researchers working tirelessly to eradicate this devastating disease. Nothing is more disheartening or disturbing than to see Dr. Anthony ...
-
Utility understated levels of cancer-causing chemical
The utility whose leaking natural gas well has driven thousands of Los Angeles residents from their homes acknowledged that it understated the number of times airborne levels of the cancer-causing chemical benzene have spiked during the crisis. Southern California Gas Co. had been saying on its website and in emails to The Associated Press that just two air samples over the past three months ...
-
Alfa Chemistry Enriches API Supply by Adding Lenalidomide, Parecoxib Sodium, and Rivaroxaban
As one of the leading chemical manufacturers and suppliers globally, Alfa Chemistry is well-prepared to provide a number of active pharmaceutical ingredients (APIs), such as donepezil and dexmedetomidine hydrochloride, for customers worldwide ranging from lab to commercial scale. Earlier this month, the company announced that three other APIs had been introduced for its global customers as well, ...
-
EPA and Partners Celebrate Reduced Lead Exposure in Children; Blood lead levels in children around Tar Creek site in Okla. greatly reduced
The U.S. Environmental Protection Agency (EPA) and its partners in Oklahoma are celebrating a significant achievement in children’s health: Since 1997, blood lead levels of children in Ottawa County and Tar Creek have drastically declined, with 0% of children in these areas showing elevated levels by 2013. “The children of Tar Creek and Ottawa County are healthier today because of ...
-
Lilly`s Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study
Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab met the primary and all key secondary endpoints in LUCENT-1, a 12-week Phase 3 induction study evaluating the efficacy and safety of mirikizumab for the treatment of patients with moderate to severe ulcerative colitis (UC). LUCENT-2, a multicenter, randomized, double-blind, placebo-controlled maintenance study of mirikizumab in ...
-
Long-term outcomes after standard graft-versus-host disease
Neovii is pleased to announce the publication of the long-term outcomes of a multicenter parallel-group randomized trial conducted in Europe and Israel. The study looked at patients after standard GvHD prophylaxis with cyclosporine A and methotrexate with or without Grafalon® (anti-human-T-lymphocyte immunoglobulin- ATLG) (60 mg/kg total dose) in adult patients receiving myeloablative ...
-
Translating great stem cell ideas into effective therapies
In science, there are a lot of terms that could easily mystify people without a research background; “translational” is not one of them. Translational research simply means to take findings from basic research and advance them into something that is ready to be tested in people in a clinical trial. Yesterday our Governing Board approved $15 million in funding for four projects as ...
-
Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo
The Companies are collaborating on an orderly transition through first half of 2022 while Sangamo explores options to advance the program, including seeking a new partner Phase 1/2 PRECIZN-1 study of investigational SAR445136 expected to be completed as planned; final patients in study expected to be dosed in third quarter of 2022 Preliminary proof-of-concept data presented at ASH 2021 showed ...
-
MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022
Data from the MANIFEST trial show durable improvements in both spleen volume and symptom score beyond 24 weeks with pelabresib in combination with ruxolitinib for JAK inhibitor-naïve patients An exploratory analysis of biomarkers from the MANIFEST trial indicates the potential for disease modification MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced results from analyses of the ...
By MorphoSys AG
-
HORIBA acquired 10,000m2 site for new reagent plant in Brazil
Production capacity of hematology reagents is to be doubled Handle expansion in medical services driven by economic growth HORIBA Group's local subsidiary in Brazil, HORIBA ABX Ltda. (1), acquired a 10,000 m2 site(2) on the outskirts of Sao Paolo, Brazil, and will construct a plant there for the manufacture of hematology reagents(3) for hospitals where hematology analyzers are used. The intent ...
-
Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease
No adverse events related to investigational SAR445136 were reported All four treated patients experienced increases in total hemoglobin, fetal hemoglobin and percent F cells; none required blood transfusions post engraftment Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 ...
-
Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics
Clinically validated lipid nanoparticle (LNP) delivery technology will further strengthen Bayer’s gene therapy portfolio High potency ionizable lipid technology and LNP carriers allow for efficient, targeted, and transient delivery of gene editing RNA components to the liver Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the ...
By Bayer AG
-
Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit
One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff Data presented today at the International Liver Cancer Association meeting at 12:25 p.m. CET Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, announced updated data from its Phase 1 ADP-A2AFP trial for patients with liver ...
-
MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that preliminary results from the ongoing Phase 1/2 study (NCT04104776) of tulmimetostat (CPI-0209) monotherapy in heavily pretreated patients with advanced cancers showed responses or disease stabilization in five cohorts with evaluable patients. Tulmimetostat is an oral, investigational next-generation selective dual inhibitor of EZH2 and ...
By MorphoSys AG
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you